References
- European Medicines Agency. Ema/65420/2015 - Kengrexal Epar Summary for the Public, 2016 August. Available from: http://www.Ema.Europa.Eu/docs/en_gb/document_library/epar_-_summary_for_the_public/human/003773/wc500188101.Pdf.
- Franchi F, Rollini F, Muniz-Lozano A, Cho JR, Angiolillo DJ. Cangrelor: A review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther 2013;11(10):1279–1291.
- Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with st-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012;5(6):797–804.
- Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R, Stavrou K, Migliorini A, Antoniucci D, Tamburino, C et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with st-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv 2015;8(1).
- Schneider DJ, Agarwal Z, Seecheran N, Keating FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv 2014;7(4):435–442.
- Rollini F, Franchi F, Angiolillo DJ. Switching p2y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 2016;13(1):11–27.
- Montalescot G, van ‘t Hof AW. Prehospital ticagrelor in st-segment elevation myocardial infarction. N Engl J Med 2014;371(24):2339.
- Montalescot G, van ‘t Hof AW, Bolognese L, WJ Cantor, Cequier A, Chettibi M, JP Collet, SG Goodman, CJ Hammett, Huber K, et al. Effect of pre-hospital ticagrelor during the first 24 h after primary percutaneous coronary intervention in patients with st-segment elevation myocardial infarction: The atlantic-h(24) analysis. JACC Cardiovasc Interv 2016;9(7):646–656.
- Franchi F, Rollini F, Cho JR, Bhatti M, DeGroat C, Ferrante E, Dunn EC, Nanavati A, Carraway E, Suryadevara S, et al. Impact of escalating loading dose regimens of ticagrelor in patients with st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Results of a prospective randomized pharmacokinetic and pharmacodynamic investigation. JACC Cardiovasc Interv 2015;8(11):1457–1467.
- Koul S, Andell P, Martinsson A, Gustav Smith J, van der Pals J, Schersten F, Jernberg T, Lagerqvist B, Erlinge D. Delay from first medical contact to primary pci and all-cause mortality: A nationwide study of patients with st-elevation myocardial infarction. J Am Heart Assoc 2014;3(2): e000486.